Drugs / LI
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01265849 | Dec 2010 → May 2020 | carcinoma of soft palate, oral cavity squamous cell carcinoma | CEL-SCI Corporation | Completed | Mixed |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01265849 ↗ |
| Route | Other | “1.0 mL peritumoral, 1.0 mL perilymphatic” NCT01265849 ↗ |